Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

@article{Kubota2008EfficacyAS,
  title={Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.},
  author={Kaoru Kubota and Yutaka Nishiwaki and Tomohide Tamura and Kazuhiko Nakagawa and Kaoru Matsui and Koshiro Watanabe and Toyoaki Hida and Masaaki Kawahara and N Katakami and Koji Takeda and Akira Yokoyama and Kazumasa Noda and Masahiro Fukuoka and Nagahiro George Saijo},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2008},
  volume={3 12},
  pages={1439-45}
}
INTRODUCTION The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy samples were analyzed to examine relationships between biomarkers and clinical outcome. METHODS This open-label phase II trial enrolled stage III/IV NSCLC patients who had progressive disease after at least one prior platinum-based chemotherapy regimen. Erlotinib was administered at a dose of 150 mg/d… CONTINUE READING
27 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Similar Papers

Loading similar papers…